Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Eli Lilly and Company
Baylor College of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
Massachusetts General Hospital
Medical College of Wisconsin
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cardinal Health 414, LLC
Hutchmed
University of Virginia
Memorial Sloan Kettering Cancer Center
Stanford University
Bayer
Sarcoma Alliance for Research through Collaboration
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eisai Inc.
Bristol-Myers Squibb
Children's Oncology Group
Eisai Inc.
Eisai Inc.
National Institutes of Health Clinical Center (CC)
Children's Oncology Group
Children's Oncology Group
OHSU Knight Cancer Institute
Dana-Farber Cancer Institute
Boehringer Ingelheim
Novartis
Children's Oncology Group
Celgene
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)